Clinical Translation of PSMA-based Imaging

1. Clinical Translation of PSMA-based Imaging Research Team Martin G. Pomper, M.D., Ph.D. - Radiology Steve Y. Cho, M.D. - Radiology Ronnie Mease, Ph.D. - Radiology Michael A. Carducci, M.D. – Medical Oncology Ronald Rodriguez, M.D., Ph.D - Urology Misop Han, M.D. - Urology Presenter Steve Y. Cho, M.D. Division of Nuclear Medicine/PET, Russell H. Morgan Department of Radiology and Radiological Science Contact Martin G. Pomper – mpomper@jhmi.edu Steve Y. Cho – scho2@jhmi.edu

2. NAAG PSMA: Overexpressed on Prostate Tumors and Solid Tumor Neovasculature • Prostate Specific Membrane Antigen (PSMA) • - Non-secreted protein • Functions both as a folate • hydrolase and a neuropeptidase • Highly expressed in prostate • cancer • Associated with tumor • aggressiveness and metastatic • potential • It is also expressed in neovasculature of most solid tumors • There are up to 106 PSMA molecules per cancer cell, making it an ideal target for imaging and therapy. CO2H F E D C outside B inside A H2N

3. [18F]DCFBC PSMA PET Imaging • [18F]DCFBC, a urea based small molecule ligand of PSMA (prostate specific membrane antigen). • Developed in Martin Pomper’s Laboratory with Ronald Mease. • Pre-Clinical Studies demonstrate high specific uptake in PSMA expressing prostate tumors. • Optimal Pharcodynamic and Pharmacokinetic Profile • Upcoming Clinical Translational Imaging Studies in Prostate Cancer and Solid Tumor Neovasculature Mease, R. C. et al. Clin Cancer Res 2008;14:3036-304